There are 702 resources available
43P - Single-arm phase II of desynchronized irinotecan plus bevacizumab, oxaliplatin, 5-fluorouracil, and folinic acid (bFOLFIRINOX-3) administration in chemorefractory metastatic colorectal cancer patients
Presenter: Francois Ghiringhelli
Session: Poster Display session
44P - BOLD-100-001: A phase II study of BOLD-100 in combination with FOLFOX in advanced mCRC patients that have failed at least two prior lines of therapy
Presenter: Grainne O'Kane
Session: Poster Display session
45P - Neoadjuvant immunotherapy with prolgolimab in locally advanced MSI/dMMR colorectal cancer: Safety and efficacy analysis
Presenter: Alexey Tryakin
Session: Poster Display session
46P - Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients (pts) with advanced metastatic colorectal cancer (mCRC) ineligible for intravenous chemotherapy: Early outcome report of a two-stage, single armed, phase II study
Presenter: Xin Wang
Session: Poster Display session
47P - Does metastatic site influence the outcome in colorectal cancer patients treated with regorafenib? Insights from the phase II randomized study SOREGATT - PRODIGE 68 - UCGI 38
Presenter: Cristina Smolenski
Session: Poster Display session
48P - Efficacy and safety of combination regimen of irinotecan plus cetuximab and envafolimab (ICE regimen) in refractory RAS/BRAF WT/MSS mCRC
Presenter: Shuai Zhang
Session: Poster Display session
49P - The impact of metformin use on the clinical outcome of metastatic colorectal cancer patients: A randomized controlled study
Presenter: Norhan Abdelhafeez
Session: Poster Display session
50P - Is liver transplantation a treatment option for unresectable colorectal liver metastases? Interim analysis of a phase II trial
Presenter: Zhihao Li
Session: Poster Display session
51P - Phase II dose expansion study of DSP107, a first-in-class fusion protein targeting CD47 and 4-1BB, in combination with atezolizumab in patients with advanced MSS colorectal cancer
Presenter: Anwaar Saeed
Session: Poster Display session
52P - Phase Ib study of pembrolizumab and XL888 in patients with advanced colorectal cancer
Presenter: Olatunji Alese
Session: Poster Display session